Analysts' Top 5 Price Targets of July 14, 2025

Harrow Inc. [US4158581094] Cantor Fitzgerald starts coverage with Overweight and a price target of $76 (116% upside potential) Cantor's experts see Harrow on a clear growth path. The company has strategically repositioned itself - moving away from traditional compounding business to a provider of branded, high-margin ophthalmic products. The medication VEVYE, used for the treatment of dry eye, is particularly highlighted, with Cantor estimating a revenue potential of up to $600 million. Overall, Harrow is viewed as one of the most promising...